• KOL
    • Hidradenitis Suppurativa
    • The Efficacy And...
    • The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Hidradenitis suppurativa,Clindamycin rifampicin,Patients hidradenitis suppurativa,Treatment hidradenitis,Patients hidradenitis,Suppurativa humans,Rifampicin combination,Patient characteristics.

      Key People For Hidradenitis Suppurativa

      Top KOLs in the world
      #1
      Gregor Borut Ernst Jemec
      hidradenitis suppurativa optical coherence atopic dermatitis
      #2
      Errol Prospero Prens
      hidradenitis suppurativa dendritic cells atopic dermatitis
      #3
      Christos Constantin Zouboulis
      hidradenitis suppurativa human sebocytes sebaceous glands
      #4
      Jean E Revuz
      toxic epidermal necrolysis hidradenitis suppurativa plasma exchange
      #5
      Lennart Emtestam
      hidradenitis suppurativa electrical impedance atopic dermatitis
      #6
      Hessel Hindrik van der Zee
      hidradenitis suppurativa perianal fistula sexual health

      The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study

      Abstract

      BACKGROUND: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.

      OBJECTIVE: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.

      METHODS: A prospective, international cohort study performed between October 2018 and August 2019.

      RESULTS: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain.

      LIMITATIONS: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline.

      CONCLUSION: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.

      Sign-in to see all concepts, it's free!

       

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.